Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32430490)

  • 1. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
    Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
    Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.
    Marzi L; Agama K; Murai J; Difilippantonio S; James A; Peer CJ; Figg WD; Beck D; Elsayed MSA; Cushman M; Pommier Y
    Mol Cancer Ther; 2018 Aug; 17(8):1694-1704. PubMed ID: 29748210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
    Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
    Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
    Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
    Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
    Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
    Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
    Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
    Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
    J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
    Pommier Y; Cushman M
    Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Topoisomerase I in the Era of Precision Medicine.
    Thomas A; Pommier Y
    Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
    Kiselev E; Ravji A; Kankanala J; Xie J; Wang Z; Pommier Y
    DNA Repair (Amst); 2020 Jan; 85():102747. PubMed ID: 31775111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
    Yi JM; Zhang XF; Huan XJ; Song SS; Wang W; Tian QT; Sun YM; Chen Y; Ding J; Wang YQ; Yang CH; Miao ZH
    Oncotarget; 2015 Apr; 6(11):8960-73. PubMed ID: 25840421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
    Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors.
    Huang SN; Pommier Y; Marchand C
    Expert Opin Ther Pat; 2011 Sep; 21(9):1285-92. PubMed ID: 21843105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
    Pfister TD; Hollingshead M; Kinders RJ; Zhang Y; Evrard YA; Ji J; Khin SA; Borgel S; Stotler H; Carter J; Divelbiss R; Kummar S; Pommier Y; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2012; 7(12):e50494. PubMed ID: 23284638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
    Strumberg D; Pommier Y; Paull K; Jayaraman M; Nagafuji P; Cushman M
    J Med Chem; 1999 Feb; 42(3):446-57. PubMed ID: 9986716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1).
    Tsuda M; Kitamasu K; Kumagai C; Sugiyama K; Nakano T; Ide H
    DNA Repair (Amst); 2020; 91-92():102849. PubMed ID: 32460231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.